Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06875310 · ClinicalTrials.gov registry record · Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Mirati Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 630
- Enrollment target
- 20
- Study locations
NCT06875310 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Mirati Therapeutics. The registered enrollment target is 630 participants, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06875310, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Mirati Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 630 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Placebo
- DRUG Pemetrexed
- DRUG Adagrasib
Study Locations (20)
Florida
- Local Institution - 0052 - Jacksonville
- Local Institution - 0680 - Ocala
- Local Institution - 0679 - Orange City
- Local Institution - 0621 - Palm Bay
- Florida Clinical Trials Group. - Tamarac
- Local Institution - 0647 - Tampa
California
- Local Institution - 0581 - Fullerton
- Local Institution - 0682 - Loma Linda
- Local Institution - 0202 - Long Beach
- Local Institution - 0623 - Santa Barbara
Illinois
- Local Institution - 0665 - Arlington Heights
- Local Institution - 0676 - Chicago
- Local Institution - 0683 - Springfield
Indiana
- Local Institution - 0684 - Fort Wayne
- Local Institution - 0423 - Munster
Alabama
- Local Institution - 0347 - Birmingham
Arkansas
- Local Institution - 0686 - Springdale
Colorado
- Local Institution - 0442 - Denver
Georgia
- Local Institution - 0031 - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 630 participants |
| Start Date | 2025-04-24 |
| Est. Completion | 2032-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06875310
The ClinicalTrials.gov registry entry for NCT06875310 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 319-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (97% higher). The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06875310 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT06875310 about?
NCT06875310 is a clinical study titled "A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)". This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mu...
What is the current status of trial NCT06875310?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 2025-04-24. Estimated completion is 2032-04-30.
What conditions does trial NCT06875310 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06875310?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Placebo (DRUG), Pemetrexed (DRUG), Adagrasib (DRUG).
Who is sponsoring clinical trial NCT06875310?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06875310 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.